Abstract
Triple combination therapy with hydroxychloroquine, sulfasalazine, and methotrexate (MTX) has been shown in double-blind, placebo-controlled studies to be significantly superior to MTX alone (Paulus 50% responses of 77% versus 33%). In long-term follow-up studies, this therapy has now been shown to be well-tolerated with continued efficacy in the majority of patients.
Original language | English (US) |
---|---|
Pages (from-to) | S53-S58 |
Journal | Clinical and experimental rheumatology |
Volume | 17 |
Issue number | 6 SUPPL. 18 |
State | Published - 1999 |
Keywords
- Combination
- DMARD
- Hydroxychloroquine
- Methotrexate
- Rheumatoid arthritis
- Sulfasalazine
ASJC Scopus subject areas
- Rheumatology
- Immunology and Allergy
- Immunology